The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada et al. · Molecular Cancer Therapeutics · 2009 · 540 citations

Wee1 Kinase, Oncogenic Agent, Medicine +15

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

Matilde Murga, Stefano Campaner, Andrés J. López‐Contreras et al. · Nature Structural & Molecular Biology · 2011 · 382 citations · Full text

Selective Killing, Medicine, Oncogenic Agent +9

Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

Halfdan Beck, Viola Nähse, Marie Sofie Yoo Larsen et al. · Molecular and Cellular Biology · 2012 · 293 citations

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

Shahryar E. Mir, Philip C. De Witt Hamer, Przemek M. Krawczyk et al. · Cancer Cell · 2010 · 290 citations · Full text

Neuro-oncology, Silico Analysis, Glioma +9

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof et al. · Clinical Cancer Research · 2011 · 274 citations · Full text